
Dichloroacetylene

Evaluation of the carcinogenicity and genotoxicity

Dutch Expert Committee on Occupational Standards,
a committee of the Health Council of the Netherlands



Aan de Staatssecretaris van Sociale Zaken en Werkgelegenheid

Onderwerp : Aanbieding advies over dichlooracetyleen
Uw kenmerk : DGV/MBO/U-932542
Ons kenmerk : U-451/JR/tvdk/459-N36
Bijlagen : 1
Datum : 16 april 2002

Mijnheer de Staatssecretaris,

Bij brief van 3 december 1993, nr DGV/MBO/U-932542, verzocht de Staatssecretaris van Welzijn, Volksgezondheid en Cultuur namens de Minister van Sociale Zaken en Werkgelegenheid de Gezondheidsraad om gezondheidskundige advieswaarden af te leiden ten behoeve van de bescherming van beroepsmatig aan stoffen blootgestelde personen. In dat kader bied ik u hierbij een advies aan over de kankerverwekkende eigenschappen van dichlooracetyleen. Het is opgesteld door de Commissie WGD van de Gezondheidsraad en beoordeeld door de Beraadsgroep Gezondheid en Omgeving.

Ik heb dit advies vandaag ter kennisname toegezonden aan de Minister van Volksgezondheid, Welzijn en Sport, de Minister van Volkshuisvesting, Ruimtelijke Ordening en Milieubeheer en de Minister van Sociale Zaken en Werkgelegenheid.

Hoogachtend,

prof. dr JA Knottnerus

Dichloroacetylene

Evaluation of the carcinogenicity and genotoxicity

Dutch Expert Committee on Occupational Standards,
a committee of the Health Council of the Netherlands

to

the Minister and State Secretary of Social Affairs and Employment

Nr 2002/04OSH, The Hague, 16 April 2002

The Health Council of the Netherlands, established in 1902, is an independent scientific advisory body. Its remit is “to advise the government and Parliament on the current level of knowledge with respect to public health issues...” (Section 21, Health Act).

The Health Council receives most requests for advice from the Ministers of Health, Welfare & Sport, Housing, Spatial Planning & the Environment, Social Affairs & Employment, and Agriculture, Nature Preservation & Fisheries. The Council can publish advisory reports on its own initiative. It usually does this in order to ask attention for developments or trends that are thought to be relevant to government policy.

Most Health Council reports are prepared by multidisciplinary committees of Dutch or, sometimes, foreign experts, appointed in a personal capacity. The reports are available to the public.

Preferred citation:

Health Council of the Netherlands: Dichloroacetylene; evaluation of the carcinogenicity and genotoxicity. The Hague: Health Council of the Netherlands, 2002; publication no. 2002/04OSH.

all rights reserved

ISBN: 90-5549-422-4

Contents

Samenvatting 7

Executive summary 8

1 Scope 9

1.1 Background 9

1.2 Committee and procedures 10

1.3 Data 10

2 Dichloroacetylene 11

2.1 Introduction 11

2.2 IARC conclusion 12

2.3 Human data 12

2.4 Animal data 13

2.5 Mutagenicity and genotoxicity 14

2.6 Evaluation 14

2.7 Recommendation for classification 14

References 15

	Annexes	16
A	Request for advice	17
B	The committee	19
C	Comments on the public review draft	21
D	IARC Monograph	22
E	Classification of substances with respect to carcinogenicity	25
F	Guideline 93/21/EEG of the European Union	27

Samenvatting

Op verzoek van de Minister van Sociale Zaken en Werkgelegenheid beoordeelt de Gezondheidsraad de kankerverwekkende eigenschappen van stoffen waaraan mensen tijdens de beroepsuitoefening kunnen worden blootgesteld. In het voorliggende rapport neemt de Commissie WGD van de Raad, die deze beoordelingen verricht, dichlooracetyleen onder de loep. De commissie heeft haar oordeel gegoten in door de Europese Unie aangegeven termen.

De commissie concludeert dat dichlooracetyleen onvoldoende is onderzocht. Hoewel de beschikbare gegevens het niet toelaten de stof te classificeren als 'kankerverwekkend voor de mens' of als 'moet beschouwd worden als kankerverwekkend voor de mens', is de commissie van mening dat waakzaamheid geboden is. De commissie adviseert daarom dichlooracetyleen te classificeren als verdacht kankerverwekkend voor de mens (vergelijkbaar met EU categorie 3B)

Executive summary

At request of the Minister of Social Affairs and Employment, the Health Council of the Netherlands evaluates the carcinogenic properties of substances at the workplace and proposes a classification with reference to the EU-directive. This evaluation is performed by the Dutch Expert Committee on Occupational Standards. The present report contains an evaluation by the committee on the carcinogenicity of dichloroacetylene.

The committee concludes that dichloroacetylene has been insufficiently investigated. While the available data do not warrant a classification as ‘carcinogenic to humans’ or as ‘should be regarded as carcinogenic to humans’, they indicate that there is cause for concern for man. The committee recommends classifying dichloroacetylene as suspected carcinogen to humans (comparable with EU category 3B).

Scope

1.1 Background

In the Netherlands a special policy is in force with respect to occupational use and exposure to carcinogenic substances. The Minister of Social Affairs and Employment has asked the Health Council of the Netherlands to study the carcinogenic properties of substances and to propose a classification with reference to an EU-directive (annex A and F). This task is carried out by the Council's Dutch Expert Committee on Occupational Standards, hereafter called the committee.

The evaluation of the carcinogenicity of a substance is based on IARC* evaluations. The original publications are not reviewed and evaluated in the text of the report, but the overall conclusion of the IARC on the carcinogenic properties is included (annex D).

In addition to classifying substances with respect to their possible carcinogenicity according to the EU Guidelines, the committee also assesses the genotoxic properties of the substances in question. The committee expresses its conclusions in the form of standard sentences (annex E).

* International Agency for Research on Cancer

1.2 Committee and procedures

The present report contains evaluations by the committee of the carcinogenicity of dichloroacetylene. The members of the committee are listed in annex B. The first draft of this report was prepared by MI Willems, from the TNO Nutrition and Food Research in Zeist, by contract with the Ministry of Social Affairs and Employment.

In 2000 the President of the Health Council released a draft of the report for public review. The individuals and organisations that commented on the draft are listed in annex C. The committee has taken these comments into account in deciding on the final version of the report.

1.3 Data

The evaluation of the carcinogenicity of dichloroacetylene has been based on several IARC evaluations (IARC86, IARC87, IARC99). The conclusion of IARC on the mutagenic or carcinogenic properties of dichloroacetylene, is included in this report (annex D). Where relevant, the original publications were reviewed and evaluated in the text.

In addition, literature has been retrieved from the online data bases Cancerlit, Toxline, and Medline, covering the period 1984 to April 1997. Scientific publications between 1997 and May 2001 were no reason for the committee to adjust her recommendation.

Dichloroacetylene

2.1 Introduction*

Name	:	dichloroacetylene
CAS no	:	7572-29-4
EEC no	:	602-069-00-8
CAS name	:	ethyne, dichloro
IUPAC name	:	dichloroacetylene
Synonyms	:	dichloroethyne
Description	:	volatile liquid
Occurrence	:	not known to occur naturally
Use	:	not known to be used commercially
Chem formula	:	C_2Cl_2
Chem structure	:	$ClC\equiv CCl$
Molecular weight	:	94.93
Boiling point (104.5 kPa)	:	33 °C (explodes)

* Data from IARC86, ACG91

Melting point (101.3 kPa)	:	-66 °C
Relative density (20°/4°C)	:	1.261
Solubility in water	:	insoluble
in organic solvents	:	soluble in ethanol, diethyl ether, acetone
Conversion factors (101.3 kPa; 20°C)	:	1 ppm = 3.96 mg/m ³ 1 mg/m ³ = 0.25 ppm
EC classification	:	E: explosive R2: risk of explosion by shock, friction, fire or other source of ignition R40: possible risks of irreversible effects Xn: harmful R48/20: harmful: danger of serious damage to health by prolonged exposure through inhalation
EU carcinogenicity class	:	3 (substances which cause concern for man owing to possible carcinogenic effects but in respect of which the available information is not adequate for making a satisfactory assessment)

2.2 IARC conclusion

In 1985, IARC concluded that there were no data available from studies in humans on the carcinogenicity of dichloroacetylene and that there was limited evidence for the carcinogenicity of the compound in experimental animals. Dichloroacetylene was not classifiable as to its carcinogenicity to humans (Group 3) (IARC86, IARC87, IARC99).

2.3 Human data

2.3.1 IARC data

No human data were presented by IARC.

2.3.2 Additional data

No additional data were found.

2.4 Animal data

2.4.1 IARC data

In male and female Wistar rats exposed to a mixture of 56 mg/m³ (14 ppm) of freshly prepared dichloroacetylene and 21.2 mg/m³ (20 ppm) acetylene as stabiliser for eighteen months (6 hours a day, 2 days a week) an increased incidence of kidney cystadenomas was found (male: 7/30, female: 3/30), while no such tumours were found in the controls, that is animals treated with air plus acetylene. One treated animal had a kidney adenocarcinoma. Furthermore, treatment resulted in increases in the incidence of liver cholangiomas (male: 6/30 versus 0/30 in controls; female: 11/30 versus 4/30) and of malignant lymphomas (female: 11/30 versus 4/30). Treatment caused decreased body weight gains and mean survival times (Reichert *et al.*, 1984 cited in IARC86). IARC was aware of the controversy concerning the neoplastic nature of cholangiomas. Furthermore, IARC noticed that statistic calculations were limited to survival differences between control and treated groups.

NMRI mice were exposed to mixtures of acetylene (as stabiliser; 21.2 mg/m³) and freshly prepared dichloroacetylene: Group I to 36 mg/m³ (9 ppm) dichloroacetylene for twelve months (6 hours a day, 1 days a week), Group II to 8 mg/m³ (2 ppm) for eighteen months (6 hours a day, 1 day a week), and Group III to 8 mg/m³ (2 ppm) dichloroacetylene for eighteen months (6 hours a day, 2 days a week). Three control groups were exposed to acetylene only. Treatment induced an increase in the incidence of kidney adenomas in male mice (I: 4/30; II: 12/30; III: 3/30; all controls: 0/30). Incidences of kidney cystadenomas and adenocarcinomas combined in male mice (I: 27/30 versus 8/30; II: 27/30 versus 4/30; III: 19/30 versus 4/30) and of kidney cystadenomas in female mice (I: 15/30 versus 0/30; II: 7/30 versus 0/30; III: 6/30 versus 4/30) were increased as well. In all treated animals in groups I and III, body weight gain and mean survival time were reduced (Reichert *et al.*, 1984 cited in IARC86). IARC noticed that statistic calculations were limited to survival differences between control and treated groups

2.4.2 Additional data

No additional data were found in the literature-databases consulted.

2.5 Mutagenicity and genotoxicity

2.5.1 IARC data

Dichloroacetylene was mutagenic in *Salmonella typhimurium* TA100, but not in TA98 when tested under aerobic conditions at 20,000 mg/m³ (5,000 ppm) for up to nine hours. Mixtures of dichloroacetylene with acetylene (used as stabiliser, see 2.4.1) were not mutagenic to *Salmonella typhimurium* in the presence or absence of a metabolic activation system from the liver of Aroclor-induced rats (Reichert *et al.*, 1983 cited in IARC86).

2.5.2 Additional information

No additional data were found in the literature databases consulted.

2.6 Evaluation

No data on the carcinogenic effects on humans are available.

The committee is of the opinion that there is limited evidence for the carcinogenicity of dichloroacetylene in experimental animals. Inhalation of dichloroacetylene induced adenocarcinomas in the kidneys of male mice. In male and female rats, dichloroacetylene induced benign tumours of the liver and the kidneys, while in female rats lymphomas were found. The opinion of the committee is in line with that of the European Union, which classified dichloroacetylene in carcinogenicity group 3.

Dichloroacetylene is mutagenic in the Ames test with *Salmonella typhimurium* TA100.

2.7 Recommendation for classification

The committee concludes that dichloroacetylene has been insufficiently investigated. While the available data do not warrant a classification as ‘carcinogenic to humans’ or as ‘should be regarded as carcinogenic to humans’, they indicate that there is cause for concern for man. The committee recommends classifying dichloroacetylene as suspected carcinogen to humans (comparable with EU category 3B).

References

-
- ACG91 American Conference of Governmental Industrial Hygienists (ACGIH). Dichloroacetylene. In: Documentation of the Threshold Limit Values and Biological Exposure Indices. 6th ed. Cincinnati OH, USA: ACGIH, 1991: 403-5.
- IARC86 International Agency for Research on Cancer (IARC). Dichloroacetylene. In: Some chemicals used in plastics and elastomers. Lyon, France: IARC, 1986: 369-78 (IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans; Vol 39).
- IARC87 International Agency for Research on Cancer (IARC). In: Overall evaluations of carcinogenicity: an updating of IARC monographs volumes 1 to 42. Lyon, France: IARC, 1987: 62 (IARC monographs on the evaluation of carcinogenic risks to humans; Suppl 7).
- IARC99 International Agency for Research on Cancer (IARC). In: Re-valuation of some organic chemicals, hydrazine and hydrogen peroxide (part three). Lyon, France: IARC, 1999: 1381-1387 (IARC monographs on the evaluation of carcinogenic risks to humans; Vol 71).
-

-
- A Request for advice
-
- B The committee
-
- C Comments on the public review draft
-
- D IARC Monograph
-
- E Classification of substances with respect to carcinogenicity
-
- F Guideline 93/21/EEG of the European Union

Annexes

Request for advice

In a letter dated October 11, 1993, ref DGA/G/TOS/93/07732A, to, the State Secretary of Welfare, Health and Cultural Affairs, the Minister of Social Affairs and Employment wrote:

Some time ago a policy proposal has been formulated, as part of the simplification of the governmental advisory structure, to improve the integration of the development of recommendations for health based occupation standards and the development of comparable standards for the general population. A consequence of this policy proposal is the initiative to transfer the activities of the Dutch Expert Committee on Occupational Standards (DECOS) to the Health Council. DECOS has been established by ministerial decree of 2 June 1976. Its primary task is to recommend health based occupational exposure limits as the first step in the process of establishing Maximal Accepted Concentrations (MAC-values) for substances at the work place.

In an addendum, the Minister detailed his request to the Health Council as follows:

The Health Council should advice the Minister of Social Affairs and Employment on the hygienic aspects of his policy to protect workers against exposure to chemicals. Primarily, the Council should report on health based recommended exposure limits as a basis for (regulatory) exposure limits for air quality at the work place. This implies:

- A scientific evaluation of all relevant data on the health effects of exposure to substances using a criteria-document that will be made available to the Health Council as part of a specific request for advice. If possible this evaluation should lead to a health based recommended exposure limit, or, in the

case of genotoxic carcinogens, a 'exposure versus tumour incidence range' and a calculated concentration in air corresponding with reference tumour incidences of 10^{-4} and 10^{-6} per year.

- The evaluation of documents review the basis of occupational exposure limits that have been recently established in other countries.
- Recommending classifications for substances as part of the occupational hygiene policy of the government. In any case this regards the list of carcinogenic substances, for which the classification criteria of the Directive of the European Communities of 27 June 1967 (67/548/EEG) are used.
- Reporting on other subjects that will be specified at a later date.

In his letter of 14 December 1993, ref U 6102/WP/MK/459, to the Minister of Social Affairs and Employment the President of the Health Council agreed to establish DECOS as a Committee of the Health Council. The membership of the Committee is given in annex B.

The committee

-
- GJ Mulder, *chairman*
professor of toxicology; Leiden University, Leiden
 - RB Beems
toxicologic pathologist; National Institute of Public Health and the Environment,
Bilthoven
 - P Boogaard
occupational physician; Shell International Petroleum Company, The Hague
 - PJ Borm
toxicologist; Heinrich Heine Universität Düsseldorf (Germany)
 - JJAM Brokamp, *advisor*
Social and Economic Council, The Hague
 - DJJ Heederik
epidemiologist; Utrecht University, Utrecht
 - LCMP Hontelez, *advisor*
Ministry of Social Affairs and Employment, The Hague
 - TM Pal
occupational physician; Netherlands Center for Occupational Diseases, Amsterdam
 - IM Rietjens
professor of toxicology; Wageningen University, Wageningen.
 - H Roelfzema, *advisor*
Ministry of Health, Welfare and Sport, The Hague
-

- T Smid
occupational hygienist; KLM Health Safety & Environment, Schiphol and professor of working conditions, Free University, Amsterdam
- GMH Swaen
epidemiologist; Maastricht University, Maastricht
- RA woutersen
toxicologic pathologist; TNO Nutrition and Food Research, Zeist
- P Wulp
occupational physician; Labour Inspectorate, Groningen
- ASAM van der Burght, *scientific secretary*
Health Council of the Netherlands, The Hague
- JM Rijnkels, *scientific secretary*
Health Council of the Netherlands, The Hague

The first draft of the present advisory report was prepared by MI Willems, from the Department of Occupational Toxicology of the TNO Nutrition and Food Research, by contract with the Ministry of Social Affairs and Employment.

Secretarial assistance was provided by mrs A van der Klugt.
Lay-out: J van Kan.

Comments on the public review draft

A draft of the present report was released in 2000 for public review. No organisations and persons have commented on the draft document.

Annex **D**

IARC Monograph

See next pages.

IARC Monograph 1986, Supplement 7.



IARC Monograph 1999, Volume 71

Annex

E

Classification of substances with respect to carcinogenicity

See next page.

The committee expresses its conclusions in the form of standard phrases:

<i>Judgement of the committee</i>	Comparable with EU class
<p>This compound is known to be carcinogenic to humans</p> <ul style="list-style-type: none"> ▪ It is genotoxic ▪ It is non-genotoxic ▪ Its potential genotoxicity has been insufficiently investigated. <p>Therefore, it is unclear whether it is genotoxic</p>	1
<p>This compound should be regarded as carcinogenic to humans</p> <ul style="list-style-type: none"> ▪ It is genotoxic ▪ It is non-genotoxic ▪ Its potential genotoxicity has been insufficiently investigated. <p>Therefore, it is unclear whether it is genotoxic</p>	2
<p>This compound is a suspected human carcinogen.</p> <p>This compound has been extensively investigated. Although there is insufficient evidence of a carcinogenic effect to warrant a classification as ‘known to be carcinogenic to humans’ or as ‘should be regarded as carcinogenic to humans’, they indicate that there is cause for concern.</p> <p>This compound has been insufficiently investigated. While the available data do not warrant a classification as ‘known to be carcinogenic to humans’ or as ‘should be regarded as carcinogenic to humans’, they indicate that there is a cause for concern.</p>	3 (A) (B)
This compound cannot be classified	not classifiable

Guideline 93/21/EEG of the European Union

4.2 Criteria for classification, indication of danger, choice of risk phrases

4.2.1 Carcinogenic substances

For the purpose of classification and labelling, and having regard to the current state of knowledge, such substances are divided into three categories:

Category 1:

Substances known to be carcinogenic to man.

There is sufficient evidence to establish a causal association between human exposure to a substance and the development of cancer.

Category 2:

Substances which should be regarded as if they are carcinogenic to man.

There is sufficient evidence to provide a strong presumption that human exposure to a substance may result in the development of cancer, generally on the basis of:

- appropriate long-term animal studies
- other relevant information.

Category 3:

Substances which cause concern for man owing to possible carcinogenic effects but in respect of which the available information is not adequate for making a satisfactory assessment.

There is some evidence from appropriate animal studies, but this is insufficient to place the substance in Category 2.

4.2.1.1 *The following symbols and specific risk phrases apply:*

Category 1 and 2:

T; R45 May cause cancer

However for substances and preparations which present a carcinogenic risk only when inhaled, for example, as dust, vapour or fumes, (other routes of exposure e.g. by swallowing or in contact with skin do not present any carcinogenic risk), the following symbol and specific risk phrase should be used:

T; R49 May cause cancer by inhalation

Category 3:

Xn; R40 Limited evidence of a carcinogenic effect

4.2.1.2 *Comments regarding the categorisation of carcinogenic substances*

The placing of a substance into Category 1 is done on the basis of epidemiological data; placing into Categories 2 and 3 is based primarily on animal experiments.

For classification as a Category 2 carcinogen either positive results in two animal species should be available or clear positive evidence in one species; together with supporting evidence such as genotoxicity data, metabolic or biochemical studies, induction of benign tumours, structural relationship with other known carcinogens, or data from epidemiological studies suggesting an association.

Category 3 actually comprises 2 sub-categories:

- a substances which are well investigated but for which the evidence of a tumour-inducing effect is insufficient for classification in Category 2. Additional experiments would not be expected to yield further relevant information with respect to classification.

- b substances which are insufficiently investigated. The available data are inadequate, but they raise concern for man. This classification is provisional; further experiments are necessary before a final decision can be made.

For a distinction between Categories 2 and 3 the arguments listed below are relevant which reduce the significance of experimental tumour induction in view of possible human exposure. These arguments, especially in combination, would lead in most cases to classification in Category 3, even though tumours have been induced in animals:

- carcinogenic effects only at very high levels exceeding the 'maximal tolerated dose'. The maximal tolerated dose is characterized by toxic effects which, although not yet reducing lifespan, go along with physical changes such as about 10% retardation in weight gain;
- appearance of tumours, especially at high dose levels, only in particular organs of certain species is known to be susceptible to a high spontaneous tumour formation;
- appearance of tumours, only at the site of application, in very sensitive test systems (e.g. i.p. or s.c. application of certain locally active compounds); if the particular target is not relevant to man;
- lack of genotoxicity in short-term tests *in vivo* and *in vitro*;
- existence of a secondary mechanism of action with the implication of a practical threshold above a certain dose level (e.g. hormonal effects on target organs or on mechanisms of physiological regulation, chronic stimulation of cell proliferation);
- existence of a species - specific mechanism of tumour formation (e.g. by specific metabolic pathways) irrelevant for man.

For a distinction between Category 3 and no classification arguments are relevant which exclude a concern for man:

- a substance should not be classified in any of the categories if the mechanism of experimental tumour formation is clearly identified, with good evidence that this process cannot be extrapolated to man;
- if the only available tumour data are liver tumours in certain sensitive strains of mice, without any other supplementary evidence, the substance may not be classified in any of the categories;
- particular attention should be paid to cases where the only available tumour data are the occurrence of neoplasms at sites and in strains where they are well known to occur spontaneously with a high incidence.